Tagrisso 40 mg Buy Film-Coated Tablets – Osimertinib

Tagrisso 40 mg Film-Coated Tablets by AstraZeneca is a cutting-edge targeted therapy containing Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Tagrisso 40 mg Osimertinib is specifically developed to treat non-small cell lung cancer (NSCLC) with EGFR mutations. Tagrisso 40 mg has revolutionized lung cancer treatment, offering patients improved progression-free survival and overall quality of life.

Tagrisso 40 mg Osimertinib works by selectively targeting and inhibiting mutated EGFR proteins, which drive the uncontrolled growth of cancer cells. Unlike earlier-generation EGFR inhibitors, Tagrisso 40 mg is uniquely effective against tumors with the T790M resistance mutation, a common cause of treatment failure in lung cancer patients.

Key Benefits & Uses of Tagrisso 40 mg Osimertinib Tablets:

• EGFR Mutation-Positive NSCLC: Tagrisso 40 mg is indicated as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations.
• T790M Mutation-Positive NSCLC: Tagrisso 40 mg Osimertinib is the gold standard for patients with NSCLC whose disease has progressed on or after EGFR-TKI therapy and tested positive for the T790M mutation.
• Brain Metastases: Tagrisso 40 mg Osimertinib has demonstrated excellent penetration into the central nervous system, making it highly effective in treating NSCLC patients with brain metastases.
• Prolonged Progression-Free Survival: Clinical trials show that Tagrisso 40 mg significantly extends progression-free survival compared to first-generation EGFR inhibitors.
• Reduced Side Effects: Tagrisso 40 mg Osimertinib is known for its improved safety profile, with fewer severe side effects compared to older EGFR inhibitors.

How to Use Tagrisso 40 mg Osimertinib Tablets:

• Dosage: The standard dosage is Tagrisso 40 mg or 80 mg once daily, as prescribed by a healthcare provider.
• Administration: Tagrisso 40 mg Tablets should be taken orally, with or without food.
• Treatment Duration: Treatment with Tagrisso 40 mg Osimertinib continues as long as clinical benefits are observed or until disease progression.

Storage Instructions:

• Store Tagrisso 40 mg Tablets below 30°C.
• Keep Tagrisso 40 mg Osimertinib in its original packaging to protect from moisture.
• Keep out of reach of children.

Potential Side Effects of Tagrisso 40 mg Osimertinib:

• Diarrhea and nausea.
• Rash and dry skin.
• Fatigue and decreased appetite.
• Pneumonitis (rare but serious).
• QT interval prolongation.
  Patients should consult their healthcare provider immediately if they experience any severe reactions while using Tagrisso 40 mg.

Why Choose Tagrisso 40 mg Osimertinib by AstraZeneca?

• Manufactured by AstraZeneca, a global leader in oncology and pharmaceutical innovation.
• Effective against EGFR and T790M mutation-positive NSCLC.
• Excellent central nervous system penetration, treating brain metastases effectively.
• Proven in clinical trials to extend survival and improve quality of life.
• Recommended as a first-line treatment by international oncology guidelines.

Real Patient Reviews:
“Tagrisso 40 mg Osimertinib gave me hope when other treatments failed. My condition improved dramatically, and I regained control over my daily life.” – Patient Testimonial

Official Resource:
AstraZeneca Tagrisso Official Page – Comprehensive prescribing information and clinical data.